Pipeline

BioMimetix is a clinical stage company with two novel drugs being developed in Phase 1 and Phase 2 trials. 

BMX-001 is a sub-cutaneous injection for oncologic conditions. 

BMX-010 is a topical for dermatologic conditions.

Program:

BMX-001

Therapeutic Indication

High-Grade Glioma

Orphan Designation
Fast-Track

  • Phase 1 100% 100%
  • Phase 2 85% 85%

Therapeutic Indication

Head and Neck Cancer
  • Phase 1/2 100% 100%
  • Phase 2 0% 0%

Therapeutic Indication

Multiple Brain Mets
  • Phase 2 25% 25%

Therapeutic Indication

Anal Cancer
  • Phase 1 50% 50%

Program:

BMX-010

Therapeutic Indication

Atopic Dermatitis
  • Phase 1 100% 100%
  • Phase 2 50% 50%

Therapeutic Indication

Pruritus (itch)
  • Phase 1 100% 100%
  • Phase 2 50% 50%

Therapeutic Indication

Psoriasis
  • Phase 1 100% 100%

Therapeutic Indication

Rosacea
  • Phase 2 50% 50%
  • Phase 2 50% 50%

Share This Webpage

Share this page with your friends!